CORZZ NASDAQ
Core Scientific, Inc. Tranche 2 Warrants
1W: +2.4%
1M: -13.9%
3M: -21.1%
YTD: -9.9%
1Y: -26.1%
$14.28
+0.50 (+3.63%)
Weekly Expected Move ±9.0%
$11
$12
$13
$14
$16
Credit Risk of going bust: higher than 86% of companies Debt: 48.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.45 (down 90%), Core Scientific, Inc. Tranche 2 Warrants would be worth roughly what it owes.
Total debt $4.30B against a stock market value of $4.58B.
Distance to default 2.08 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.15B (short-term plus half of long-term), stock volatility 72.5%; Altman Z'' -5.99. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $1.45 (down 90%), Core Scientific, Inc. Tranche 2 Warrants would be worth roughly what it owes.
Total debt $4.30B against a stock market value of $4.58B.
Distance to default 2.08 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.15B (short-term plus half of long-term), stock volatility 72.5%; Altman Z'' -5.99. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
📊 Key Metrics
TTM$440M
Revenue
+26.4% YoY
$-1,435M
Net Income
-33.3% YoY
$-968M
Free Cash Flow
-277.2% YoY
42.7%
Gross Margin
-43.9%
Op. Margin
-703.6%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE82.4%
ROA-39.7%
ROIC-107.6%
Valuation
P/E-3.4
P/B-1.9
EV/EBITDA-7.9
Leverage
Debt/Equity-1.78
Current Ratio0.89
Interest Cov.-47.4x
Quality Scores
Piotroski F4/9
Altman Z-1.73
Beneish M-0.82